RU94016406A - Method of treatment of erysipelatous inflammation - Google Patents

Method of treatment of erysipelatous inflammation

Info

Publication number
RU94016406A
RU94016406A RU94016406/14A RU94016406A RU94016406A RU 94016406 A RU94016406 A RU 94016406A RU 94016406/14 A RU94016406/14 A RU 94016406/14A RU 94016406 A RU94016406 A RU 94016406A RU 94016406 A RU94016406 A RU 94016406A
Authority
RU
Russia
Prior art keywords
treatment
erysipelatous
inflammation
effect
erysipelatous inflammation
Prior art date
Application number
RU94016406/14A
Other languages
Russian (ru)
Other versions
RU2126659C1 (en
Inventor
В.А. Козлов
И.В. Козлов
В.В. Касимова
Original Assignee
Уральский государственный медицинский институт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уральский государственный медицинский институт filed Critical Уральский государственный медицинский институт
Priority to RU94016406A priority Critical patent/RU2126659C1/en
Publication of RU94016406A publication Critical patent/RU94016406A/en
Application granted granted Critical
Publication of RU2126659C1 publication Critical patent/RU2126659C1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FIELD: medicine, in particular, cryotherapy. SUBSTANCE: inflammatory focus is subjected to the effect of liquid nitrogen for 20 to 25 s at a distance of 3 to 5 cm to the skin. EFFECT: reduced term of treatment of patients that are ill with erysipelatous inflammation.

Claims (1)

Сущность способа заключается в воздействии на воспалительный очаг жидким азотом в течение 20 - 25 с на расстоянии от кожи 3 - 5см. Способ позволяет сократить сроки лечения больных рожистым воспалением.The essence of the method consists in exposing the inflammatory focus to liquid nitrogen for 20 to 25 seconds at a distance from the skin of 3-5 cm. The method allows to reduce the treatment time for patients with erysipelas.
RU94016406A 1994-04-27 1994-04-27 Erysipelatous inflammation treatment method RU2126659C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU94016406A RU2126659C1 (en) 1994-04-27 1994-04-27 Erysipelatous inflammation treatment method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU94016406A RU2126659C1 (en) 1994-04-27 1994-04-27 Erysipelatous inflammation treatment method

Publications (2)

Publication Number Publication Date
RU94016406A true RU94016406A (en) 1996-08-10
RU2126659C1 RU2126659C1 (en) 1999-02-27

Family

ID=20155527

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94016406A RU2126659C1 (en) 1994-04-27 1994-04-27 Erysipelatous inflammation treatment method

Country Status (1)

Country Link
RU (1) RU2126659C1 (en)

Also Published As

Publication number Publication date
RU2126659C1 (en) 1999-02-27

Similar Documents

Publication Publication Date Title
TR199801180T2 (en) New compounds with analgesic effect.
ATE125445T1 (en) ORAL COMPOSITION FOR THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES.
NO844017L (en) SPORABLE CONJUGATES OF METALLOTHIONEIN AND TARGET-SEARCHING BIOLOGICAL ACTIVE MOLECULES
ES2191068T3 (en) PROFILACTIC AND THERAPEUTIC TREATMENT OF SKIN SENSITIZATION AND IRRITATION.
ES2059965T3 (en) A PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY DISEASES.
DK0607128T3 (en) Drugs and their manufacture and use in the control of pain and / or inflammation in animals and humans
RU94022017A (en) Method of treatment of acne or bread pseudofolliculitis, method of composition preparing, use of enzyme ornitine decarboxylase inhibitor for acne and bread folliculitis treatment
DE69634430D1 (en) FORMULATION FOR WOUND HEALING WITH HUMAN PLASMA FIBRONECTIN
DK0396184T3 (en) Use of ketoconazole and a retinoid for the treatment of acne vulgaris
AU618443B2 (en) The use of the active substance azelastine in combatting psoriasis disorders and inflammatory disorders
ES2151607T3 (en) GROWTH AND DIFFERENTIATION FACTOR 12.
DK47089A (en) SUBSTANCE WITH DAMAGING EFFECT ON TIMAL TUMORS, PROCEDURES FOR THE PREPARATION OF SUCH AGENTS AND THE USE OF THESE FOR THERAPEUTIC TREATMENT OF CANCER
NO894222L (en) PROCEDURES FOR THE TREATMENT AND PROPHYLAXY OF PNEUMOCYTIS CARINII PNEUMONI AND OTHER DISEASES AND COMPOUNDS AND FORMULATIONS FOR USE IN THE ABOVE METHODS.
BG101126A (en) The use of muramylpeptide compounds
ES8403884A1 (en) Antiinflammatory and/or analgesic 2,3-Diaryl-5-halo thiophenes.
TR199801184T2 (en) New compounds with analgesic action.
RU94016406A (en) Method of treatment of erysipelatous inflammation
ES8106498A1 (en) 4,5-Diaryl-alpha-polyfluoroalkyl-1H-pyrrole-2-methanols and 1-(4,5-diaryl-1H-pyrrol-2-yl)-polyfluoroalkanones, processes for preparing them and pharmaceutical compositions.
SE8102161L (en) "3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic
FR2417494A1 (en) Sodium paracetamol hemi:succinate - is very soluble in water and without unpleasant taste of paracetamol
ATE86611T1 (en) TOPICAL PHARMACEUTICALS FOR THE TREATMENT OF ACNE AND SKIN DISEASES.
ATE36333T1 (en) HYDANTOIN CONTAINING THERAPEUTIC AGENT.
RU94024337A (en) Antimetastatic agent
SU628905A1 (en) Termal burn treatment method
RU94004903A (en) Antitumor and immunomodulating agents and methods of treatment of oncological patients, cutaneous and trophic ulcers